Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-16T04:27:10.955Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of Long-Term Deutetrabenazine Treatment in Patients with Tardive Dyskinesia and Underlying Psychiatric or Mood Disorders

Published online by Cambridge University Press:  28 April 2022

Robert A. Hauser ,
Hadas Barkay ,
Hubert H. Fernandez ,
Stewart A. Factor ,
Joohi Jimenez-Shahed ,
Nicholas Gross ,
Leslie Marinelli ,
Amanda Wilhelm ,
Mark Forrest Gordon  and
Juha-Matti Savola
...Show all authors
Robert A. Hauser
Affiliation:
University of South Florida Parkinsons Disease and Movement Disorders Center, Tampa, FL, USA
Hadas Barkay
Affiliation:
Teva Pharmaceuticals, Netanya, Israel
Hubert H. Fernandez
Affiliation:
Cleveland Clinic, Cleveland, OH, USA
Stewart A. Factor
Affiliation:
Emory University, Atlanta, GA, USA
Joohi Jimenez-Shahed
Affiliation:
Icahn School of Medicine at Mount Sinai, New York, NY, USA
Nicholas Gross
Affiliation:
Teva Pharmaceuticals, West Chester, PA, USA
Leslie Marinelli
Affiliation:
Teva Pharmaceuticals, West Chester, PA, USA
Amanda Wilhelm
Affiliation:
Teva Pharmaceuticals, West Chester, PA, USA
Mark Forrest Gordon
Affiliation:
Teva Pharmaceuticals, West Chester, PA, USA
Juha-Matti Savola
Affiliation:
Teva Pharmaceuticals, Basel, Switzerland
Karen E. Anderson
Affiliation:
Georgetown University, Washington, DC, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Deutetrabenazine is FDA-approved for the treatment of tardive dyskinesia (TD) in adults. In two 12-week pivotal trials (ARM-TD/AIM-TD), deutetrabenazine significantly improved Abnormal Involuntary Movement Scale (AIMS) scores and was well-tolerated. This post hoc analysis examined the efficacy and safety of long-term deutetrabenazine treatment in TD patients with comorbid psychiatric illness, including schizophrenia/schizoaffective disorder and mood disorders (bipolar/depression/other).

Methods

Patients who completed ARM-TD or AIM-TD enrolled in the 3-year, open-label extension (OLE) study. Deutetrabenazine was titrated based on dyskinesia control and tolerability. Change from baseline in total motor AIMS score, Patient Global Impression of Change (PGIC), Clinical Global Impression of Change (CGIC), and adverse events (AEs) were analyzed in subgroups by comorbid psychiatric illness.

Results

A total of 337 patients in the OLE study were included in the analysis: 205 patients with schizophrenia/schizoaffective disorder (mean age, 55 years; 50% male; 6.4 years since diagnosis; 92% taking DRA) and 131 patients with mood disorders (mean age, 60 years; 35% male; 4.6 years since diagnosis; 50% taking DRA). At week 145, mean ± SE dose was 40.4 ± 1.1 mg/day for schizophrenia/schizoaffective disorder (n = 88) and 38.5 ± 1.2 mg/day for mood disorders (n = 72). Mean ± SE change from baseline in AIMS score at week 145 was −6.3 ± 0.49 and −7.1 ± 0.58, 56% and 72% achieved PGIC treatment success, and 66% and 82% achieved CGIC treatment success in schizophrenia/schizoaffective disorder and mood disorder patients, respectively. Overall AE incidence (exposure-adjusted incidence rates [incidence/patient-years]) was low: any, 1.02 and 1.71; serious, 0.10 and 0.12; leading to discontinuation, 0.07 and 0.05).

Conclusion

Long-term deutetrabenazine treatment provided clinically meaningful improvements in TD-related movements, with a favorable safety profile, regardless of underlying comorbid psychiatric illness.

Funding

Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel

Type
Abstracts
Information
CNS Spectrums , Volume 27 , Issue 2 , April 2022 , pp. 245 - 246
Copyright
© The Author(s), 2022. Published by Cambridge University Press